Journal
ONCOIMMUNOLOGY
Volume 3, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.27560
Keywords
checkpoint inhibitors; immunotherapy; melanoma; solid tumors; survival; ulceration
Categories
Funding
- Bristol-Myers Squibb
Ask authors/readers for more resources
Accumulating data from patients treated with checkpoint inhibitors and other immunomodulatory agents indicate that harnessing the power of the immune system is integral to achieve improve long-term cancer containment rates and prolong patient survival. Due to their mechanism of action, immunotherapeutic approaches have the potential to be effective against almost every tumor type. Durable responses to immunotherapy and prolonged patient survival have indeed been documented in individuals with melanoma, as well as kidney and lung cancer. These advances call for the re-evaluation of how clinical benefit is measured in an era in which long-term tumor control and survival are achievable treatment goals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available